La traduction de cette page est expérimentale et en cours de développement. N'hésitez pas à vos !

Simcere Pharmaceutical Group Bilan de santé

Santé financière contrôle des critères 6/6

Simcere Pharmaceutical Group possède un total de capitaux propres de CN¥6.9B et une dette totale de CN¥1.0B, ce qui porte son ratio d'endettement à 14.5%. Son actif total et son passif total sont CN¥11.7B et de CN¥4.8B. L'EBIT de Simcere Pharmaceutical Group est CN¥935.6M ce qui fait que son ratio de couverture des intérêts -97.9. Elle dispose de liquidités et de placements à court terme de CN¥3.1B.

Informations clés

14.5%

Ratio d'endettement

CN¥1.00b

Dette

Ratio de couverture des intérêts	-97.9x
Argent liquide	CN¥3.06b
Fonds propres	CN¥6.91b
Total du passif	CN¥4.80b
Total des actifs	CN¥11.71b

Mises à jour récentes de la santé financière

Pas de mise à jour

Recent updates

Simcere Pharmaceutical Group Limited (HKG:2096) Not Lagging Market On Growth Or Pricing

Jul 29

Why Simcere Pharmaceutical Group's (HKG:2096) Shaky Earnings Are Just The Beginning Of Its Problems

May 01

Simcere Pharmaceutical Group Limited's (HKG:2096) Business And Shares Still Trailing The Market

Dec 29

Need To Know: Analysts Just Made A Substantial Cut To Their Simcere Pharmaceutical Group Limited (HKG:2096) Estimates

Aug 28

Are Investors Undervaluing Simcere Pharmaceutical Group Limited (HKG:2096) By 40%?

Jun 03

Analysts Just Shaved Their Simcere Pharmaceutical Group Limited (HKG:2096) Forecasts Dramatically

Apr 06

Estimating The Intrinsic Value Of Simcere Pharmaceutical Group Limited (HKG:2096)

Jan 10

With EPS Growth And More, Simcere Pharmaceutical Group (HKG:2096) Makes An Interesting Case

Aug 16

Simcere Pharmaceutical Group (HKG:2096) Has Announced A Dividend Of HK$0.18

Jun 27

Analyse de la situation financière

Passif à court terme: Les actifs à court terme de 2096 ( CN¥6.4B ) dépassent ses passifs à court terme ( CN¥3.1B ).

Passif à long terme: Les actifs à court terme de 2096 ( CN¥6.4B ) dépassent ses passifs à long terme ( CN¥1.7B ).

Historique et analyse du ratio d'endettement

Niveau d'endettement: 2096 dispose de plus de liquidités que de sa dette totale.

Réduire la dette: Le ratio d'endettement de 2096 a été réduit de 165.4% à 14.5% au cours des 5 dernières années.

Couverture de la dette: La dette de 2096 est bien couverte par le flux de trésorerie opérationnel ( 109.2% ).

Couverture des intérêts: 2096 gagne plus d'intérêts qu'il n'en paie, donc la couverture des paiements d'intérêts n'est pas un problème.

Simcere Pharmaceutical Group Bilan de santé

Santé financière contrôle des critères 6/6

Informations clés

Mises à jour récentes de la santé financière

Recent updates

First half 2024 earnings released: EPS: CN¥0.18 (vs CN¥0.87 in 1H 2023)

Simcere Pharmaceuticals Group Ltd. Announces Breakthrough Therapy Designation for Sanbexin Sublingual Tablets Granted by the United States Food and Drug Administration

First half 2024 earnings released: EPS: CN¥0.18 (vs CN¥0.87 in 1H 2023)

Simcere Pharmaceutical Group Limited Obtains Clinical Trial Approval Issued by the National Medical Products Administration

Simcere Pharmaceutical Group Limited to Report First Half, 2024 Results on Aug 21, 2024

Now 22% overvalued

Simcere Pharmaceutical Group Limited (HKG:2096) Not Lagging Market On Growth Or Pricing

Simcere Pharmaceutical Group Limited Announces New Drug Application of Quviviq (Daridorexant Hydrochloride Tablets) Has Been Accepted by the National Medical Products Administration

Simcere Pharmaceutical Group Limited Announces Regular Approval of Xiannuoxin, an Anti-Sars-Cov-2 Innovative Drug

Co-Founder recently sold HK$1.2m worth of stock

Simcere Pharmaceutical Group Limited and Mabpharm Limited Announce Approval on the Marketing of ENLITUO in China by the National Medical Products Administration of China

Simcere Pharmaceutical Group Limited (SEHK:2096) commences an Equity Buyback for 260,976,161 shares, representing 10% of its issued share capital, under the authorization approved on June 14, 2024.

Upcoming dividend of CN¥0.16 per share

Simcere Pharmaceutical Group Limited Announces Phase III Clinical Study of Daridorexant Hydrochloride Tablets in the Treatment of Insomia Patients in China

Simcere Pharmaceutical Group Limited and Idorsia Pharmaceuticals Ltd. Announces the Hypnotics Daridorexant Hydrochloride Tablets Obtains the Certificate of Drug/ Product Registration Issued by the Pharmacy and Poisons Board of Hong Kong

Why Simcere Pharmaceutical Group's (HKG:2096) Shaky Earnings Are Just The Beginning Of Its Problems

Full year 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Consensus revenue estimates fall by 14%

Dividend of CN¥0.16 announced

Simcere Pharmaceutical Group Limited, Annual General Meeting, Jun 14, 2024

Consensus EPS estimates fall by 37%

Simcere Pharmaceutical Group Limited Announces New Drug Application of Suvemcitug for Injection Accepted by the National Medical Products Administration of China

Simcere Pharmaceutical Group Limited Announces Clinical Trial Approval for Sim0500 for Injection (A Humanized Gprc5d-Bcma-Cd3 Trispecific Antibody) Issued by the National Medical Products Administration

Simcere Pharmaceutical Group Limited Announces Approval of the Investigational New Drug for SIM0500

Simcere Pharmaceutical Group Limited to Report Fiscal Year 2023 Results on Mar 20, 2024

Simcere Pharmaceutical Group Limited Provides Consolidated Earnings Guidance for the Year Ended December 31, 2023

Consensus EPS estimates fall by 35%

Simcere Pharmaceutical Group Limited Announces Publication by New England Journal of Medicine About Phase II/III Clinical Studies Results of XIANNUOXIN for Treatment of Adult Patients with Mild-yo-Moderate COVID-19

Simcere Pharmaceutical Group Limited Announces Clinical Trial Approval for SIM0501 Tablets

Simcere Pharmaceutical Group Limited's (HKG:2096) Business And Shares Still Trailing The Market

Simcere Pharmaceutical Group Limited Announces Localization Application of COSELA (Trilaciclib Hydrochloride for Injection) Approved by the National Medical Products Administration of China

Simcere Pharmaceutical Group Limited Announces Approval of Investigational New Drug for SIM0501 (An Usp1 Small-Molecule Inhibitor) Issued by U.S. Food and Drug Administration

Simcere Pharmaceutical Group Limited and Neurodawn Pharmaceutical Co., Ltd. Obtains Clinical Trial Approval Issued by the National Medical Products Administration

Simcere Pharmaceutical Group Limited Announces Approval of COSELA (Trilaciclib Hydrochloride for Injection) Approved by the National Medical Products Administration of China

Simcere Pharmaceutical Group Limited Announces the Clinical Trial Approval for New Indication of Sim0237 for Injection (Anti-Pd-L1/IL-15 Bispecific Antibody) Issued by the National Medical Products Administration

Co-Founder recently bought HK$1.2m worth of stock

Need To Know: Analysts Just Made A Substantial Cut To Their Simcere Pharmaceutical Group Limited (HKG:2096) Estimates

Consensus revenue estimates fall by 22%

First half 2023 earnings released: EPS: CN¥0.87 (vs CN¥0.024 in 1H 2022)

Simcere Pharmaceutical Group Limited to Report First Half, 2023 Results on Aug 21, 2023

Simcere Pharmaceutical Group Limited Obtains Clinical Trial Approval Issued by National Medical Products Administration

Simcere Pharmaceutical Group Limited Obtains Clinical Trial Approval Issued by National Medical Products Administration

Simcere Pharmaceutical Group Limited (SEHK:2096) commences an Equity Buyback Plan for 266,404,561 shares, representing 10% of its issued share capital, under the authorization approved on June 15, 2023.

Simcere Pharmaceutical Group Limited (SEHK:2096) commences an Equity Buyback Plan for 266,404,561 shares, representing 10% of its issued share capital, under the authorization approved on June 15, 2023.

Co-Founder recently sold HK$710k worth of stock

New minor risk - Insider selling

Co-Founder recently sold HK$2.3m worth of stock

Simcere Pharmaceutical Group Limited Approves Final Cash Dividend for the Year Ended December 31, 2022, Payable on 12 July 2023

Co-Founder recently bought HK$1.5m worth of stock

Upcoming dividend of CN¥0.16 per share at 2.3% yield

Are Investors Undervaluing Simcere Pharmaceutical Group Limited (HKG:2096) By 40%?

Co-Founder recently sold HK$3.1m worth of stock

Full year 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Investor sentiment improves as stock rises 15%

Consensus revenue estimates fall by 13%

Analysts Just Shaved Their Simcere Pharmaceutical Group Limited (HKG:2096) Forecasts Dramatically

Now 23% undervalued

Simcere Pharmaceutical Group Limited Announces Conditional Approval for Marketing in China of Anti-Sars-Cov-2 Innovative Drug Xiannuoxin Tm Granted by the National Medical Products Administration

Simcere Pharmaceutical Group Limited Announces Appointment Wang Xi as an Executive Director and the Appointment of Sung Ka Woon as an Independent Non-Executive Director

Investor sentiment deteriorated over the past week

Simcere Pharmaceutical Group Limited Announces Acceptance of New Drug Application of Anti-SARS-CoV-2 Innovative Drug Xiannuoxin (Simnotrelvir Tablets/Ritonavir Tablets (Co-Packaged)) by the National Medical Products Administration

Now 24% undervalued

Co-Founder recently bought HK$7.9m worth of stock

Estimating The Intrinsic Value Of Simcere Pharmaceutical Group Limited (HKG:2096)

Simcere Pharmaceutical Group Limited Appoints Mr. Tang Renhong as the Chairman of the Board of Directors and Chief Executive Officer of Simcere Zaiming Pharmaceutical Co., Ltd., with Effect from January 1, 2023

Simcere Pharmaceutical Group Limited Announces - the Clinical Trial Approval for SIM0348 Injection (Humanized TIGIT/PVRIG Bispecific Antibody) Issued by the National Medical Products Administration

Now 20% undervalued

Investor sentiment improved over the past week

Simcere Pharmaceutical Group Announces Phase II/III Clinical Trial of Its 3Cl-Targeting anti-SARS-CoV-2 Drug Candidate Complete All Patients Enrollment

Simcere Pharmaceutical Group Limited Announces A Phase II/III Clinical Study of Anti-Sars-COV-2 Drug Candidate XIANNUOXIN (SIM0417) Complete All Patients Enrollment

Investor sentiment deteriorated over the past week

Simcere Pharmaceutical Group Limited Announces A Multi-Center, Randomized, Double-Blind, Parallel and Placebo-Controlled Phase III Clinical Study

Insufficient new directors

Simcere Pharmaceutical Group Limited Announces Executive Changes

Investor sentiment improved over the past week